Pub Date : 2024-11-13Print Date: 2024-10-01DOI: 10.1183/16000617.0118-2024
Martina Votto, Annalisa De Silvestri, Lorenzo Postiglione, Maria De Filippo, Sara Manti, Stefania La Grutta, Gian Luigi Marseglia, Amelia Licari
Background: Asthma exacerbations in children pose a significant burden on healthcare systems and families. While traditional risk assessment tools exist, artificial intelligence (AI) offers the potential for enhanced prediction models.
Objective: This study aims to systematically evaluate and quantify the performance of machine learning (ML) algorithms in predicting the risk of hospitalisation and emergency department (ED) admission for acute asthma exacerbations in children.
Methods: We performed a systematic review with meta-analysis, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The risk of bias and applicability for eligible studies was assessed according to the prediction model study risk of bias assessment tool (PROBAST). The protocol of our systematic review was registered in the International Prospective Register of Systematic Reviews.
Results: Our meta-analysis included seven articles encompassing a total of 17 ML-based prediction models. We found a pooled area under the curve (AUC) of 0.67 (95% CI 0.61-0.73; I2=99%; p<0.0001 for heterogeneity) for models predicting ED admission, indicating moderate accuracy. Notably, models predicting child hospitalisation demonstrated a higher pooled AUC of 0.79 (95% CI 0.76-0.82; I2=95%; p<0.0001 for heterogeneity), suggesting good discriminatory power.
Conclusion: This study provides the most comprehensive assessment of AI-based algorithms in predicting paediatric asthma exacerbations to date. While these models show promise and ML-based hospitalisation prediction models, in particular, demonstrate good accuracy, further external validation is needed before these models can be reliably implemented in real-life clinical practice.
背景:儿童哮喘加重给医疗系统和家庭带来了沉重负担。虽然存在传统的风险评估工具,但人工智能(AI)为增强预测模型提供了潜力:本研究旨在系统评估和量化机器学习(ML)算法在预测儿童哮喘急性加重住院和急诊科(ED)入院风险方面的性能:我们按照系统综述和荟萃分析首选报告项目(PRISMA)指南进行了系统综述和荟萃分析。根据预测模型研究偏倚风险评估工具(PROBAST)评估了符合条件的研究的偏倚风险和适用性。我们的系统综述方案已在国际系统综述前瞻性注册中心注册:我们的荟萃分析包括 7 篇文章,共涉及 17 个基于 ML 的预测模型。我们发现汇总的曲线下面积(AUC)为 0.67(95% CI 0.61-0.73;I2=99%;p2=95%;pConclusion):本研究对基于人工智能的算法预测儿科哮喘恶化进行了迄今为止最全面的评估。虽然这些模型显示出了良好的前景,尤其是基于 ML 的住院预测模型显示出了良好的准确性,但在将这些模型可靠地应用于实际临床实践之前,还需要进一步的外部验证。
{"title":"Predicting paediatric asthma exacerbations with machine learning: a systematic review with meta-analysis.","authors":"Martina Votto, Annalisa De Silvestri, Lorenzo Postiglione, Maria De Filippo, Sara Manti, Stefania La Grutta, Gian Luigi Marseglia, Amelia Licari","doi":"10.1183/16000617.0118-2024","DOIUrl":"10.1183/16000617.0118-2024","url":null,"abstract":"<p><strong>Background: </strong>Asthma exacerbations in children pose a significant burden on healthcare systems and families. While traditional risk assessment tools exist, artificial intelligence (AI) offers the potential for enhanced prediction models.</p><p><strong>Objective: </strong>This study aims to systematically evaluate and quantify the performance of machine learning (ML) algorithms in predicting the risk of hospitalisation and emergency department (ED) admission for acute asthma exacerbations in children.</p><p><strong>Methods: </strong>We performed a systematic review with meta-analysis, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The risk of bias and applicability for eligible studies was assessed according to the prediction model study risk of bias assessment tool (PROBAST). The protocol of our systematic review was registered in the International Prospective Register of Systematic Reviews.</p><p><strong>Results: </strong>Our meta-analysis included seven articles encompassing a total of 17 ML-based prediction models. We found a pooled area under the curve (AUC) of 0.67 (95% CI 0.61-0.73; I<sup>2</sup>=99%; p<0.0001 for heterogeneity) for models predicting ED admission, indicating moderate accuracy. Notably, models predicting child hospitalisation demonstrated a higher pooled AUC of 0.79 (95% CI 0.76-0.82; I<sup>2</sup>=95%; p<0.0001 for heterogeneity), suggesting good discriminatory power.</p><p><strong>Conclusion: </strong>This study provides the most comprehensive assessment of AI-based algorithms in predicting paediatric asthma exacerbations to date. While these models show promise and ML-based hospitalisation prediction models, in particular, demonstrate good accuracy, further external validation is needed before these models can be reliably implemented in real-life clinical practice.</p>","PeriodicalId":12166,"journal":{"name":"European Respiratory Review","volume":"33 174","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-13Print Date: 2024-10-01DOI: 10.1183/16000617.0272-2023
Budjav Jadamba, Yang Jin, Heedoo Lee
Extracellular vesicles (EVs) released by various cells play crucial roles in intercellular communication within the respiratory system. This review explores the historical context and significance of research into extracellular vesicles. Categorised into exosomes (sized 30-150 nm), microvesicles (sized 50-1000 nm) and apoptotic bodies (sized 500-2000nm), based on their generation mechanisms, extracellular vesicles carry diverse cargoes of biomolecules, including proteins, lipids and nucleic acids. Respiratory ailments are the primary contributors to both mortality and morbidity across various populations globally, significantly impacting public health. Recent studies have underscored the pivotal role of extracellular vesicles, particularly their cargo content, in mediating intercellular communication between lung cells in respiratory diseases. This comprehensive review provides insights into extracellular vesicle mechanisms and emphasises their significance in major respiratory conditions, including acute lung injury, COPD, pulmonary hypertension, pulmonary fibrosis, asthma and lung cancer.
{"title":"Harmonising cellular conversations: decoding the vital roles of extracellular vesicles in respiratory system intercellular communications.","authors":"Budjav Jadamba, Yang Jin, Heedoo Lee","doi":"10.1183/16000617.0272-2023","DOIUrl":"10.1183/16000617.0272-2023","url":null,"abstract":"<p><p>Extracellular vesicles (EVs) released by various cells play crucial roles in intercellular communication within the respiratory system. This review explores the historical context and significance of research into extracellular vesicles. Categorised into exosomes (sized 30-150 nm), microvesicles (sized 50-1000 nm) and apoptotic bodies (sized 500-2000nm), based on their generation mechanisms, extracellular vesicles carry diverse cargoes of biomolecules, including proteins, lipids and nucleic acids. Respiratory ailments are the primary contributors to both mortality and morbidity across various populations globally, significantly impacting public health. Recent studies have underscored the pivotal role of extracellular vesicles, particularly their cargo content, in mediating intercellular communication between lung cells in respiratory diseases. This comprehensive review provides insights into extracellular vesicle mechanisms and emphasises their significance in major respiratory conditions, including acute lung injury, COPD, pulmonary hypertension, pulmonary fibrosis, asthma and lung cancer.</p>","PeriodicalId":12166,"journal":{"name":"European Respiratory Review","volume":"33 174","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-13Print Date: 2024-10-01DOI: 10.1183/16000617.0101-2024
Raphael Borie, Laureline Berteloot, Caroline Kannengiesser, Matthias Griese, Aurelie Cazes, Bruno Crestani, Alice Hadchouel, Marie Pierre Debray
The main monogenic causes of pulmonary fibrosis in adults are mutations in telomere-related genes. These mutations may be associated with extrapulmonary signs (hepatic, haematological and dermatological) and typically present radiologically as usual interstitial pneumonia or unclassifiable fibrosis. In children, the monogenic causes of pulmonary fibrosis are dominated by mutations in surfactant-related genes. These mutations are not associated with extrapulmonary signs and often manifest radiologically as unclassifiable fibrosis with cysts that can lead to chest wall deformities in adults. This review discusses these mutations, along with most of the monogenic causes of interstitial lung disease, including interferon-related genes, mutations in genes causing cystic lung disease, Hermansky-Pudlak syndrome, pulmonary alveolar proteinosis, lysinuric protein intolerance and lysosomal storage disorders, and their pulmonary and extrapulmonary manifestations.
{"title":"Rare genetic interstitial lung diseases: a pictorial essay.","authors":"Raphael Borie, Laureline Berteloot, Caroline Kannengiesser, Matthias Griese, Aurelie Cazes, Bruno Crestani, Alice Hadchouel, Marie Pierre Debray","doi":"10.1183/16000617.0101-2024","DOIUrl":"10.1183/16000617.0101-2024","url":null,"abstract":"<p><p>The main monogenic causes of pulmonary fibrosis in adults are mutations in telomere-related genes. These mutations may be associated with extrapulmonary signs (hepatic, haematological and dermatological) and typically present radiologically as usual interstitial pneumonia or unclassifiable fibrosis. In children, the monogenic causes of pulmonary fibrosis are dominated by mutations in surfactant-related genes. These mutations are not associated with extrapulmonary signs and often manifest radiologically as unclassifiable fibrosis with cysts that can lead to chest wall deformities in adults. This review discusses these mutations, along with most of the monogenic causes of interstitial lung disease, including interferon-related genes, mutations in genes causing cystic lung disease, Hermansky-Pudlak syndrome, pulmonary alveolar proteinosis, lysinuric protein intolerance and lysosomal storage disorders, and their pulmonary and extrapulmonary manifestations.</p>","PeriodicalId":12166,"journal":{"name":"European Respiratory Review","volume":"33 174","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Lung cancer ranks as the leading cause of cancer-related deaths worldwide. There is evidence that second-hand smoke (SHS) exposure is a risk factor for the development of lung cancer in never-smokers. This systematic review and meta-analysis aims to provide the most accurate quantification of the association between SHS exposure and lung cancer risk in never-smokers.
Materials and methods: Through the use of an innovative method to identify original publications, we conducted a systematic review of the literature, with corresponding meta-analysis, of all epidemiological studies evaluating the association between SHS exposure and lung cancer risk among never-smokers, published up to May 2023. Pooled relative risks were obtained using random-effects models. Dose-response relationships were derived using log-linear functions or cubic splines.
Results: Out of 126 identified eligible studies, 97 original articles were included in the meta-analysis. The pooled relative risk for lung cancer for overall exposure to SHS was 1.24 (95% CI 1.16-1.32, number of articles, n=82). Setting-specific relative risks were 1.20 (95% CI 1.12-1.28, n=67) for SHS exposure at home, 1.38 (95% CI 1.28-1.62, n=30) at a workplace, 1.37 (95% CI 1.22-1.53, n=28) at home or a workplace and 1.27 (95% CI 1.11-1.44, n=24) in nonspecified settings. The risk of lung cancer significantly increased with the duration, intensity and pack-years of SHS exposure.
Conclusions: This meta-analysis shows that exposure to SHS increases by more than 20% the risk of lung cancer among never-smokers, providing definitive evidence of the association between SHS exposure and lung cancer risk.
背景:肺癌是全球癌症相关死亡的首要原因。有证据表明,二手烟(SHS)暴露是导致从不吸烟者罹患肺癌的一个风险因素。本系统综述和荟萃分析旨在最准确地量化二手烟暴露与从不吸烟者患肺癌风险之间的关系:通过使用创新方法识别原始出版物,我们对截至 2023 年 5 月发表的所有评估 SHS 暴露与从不吸烟者肺癌风险之间关系的流行病学研究文献进行了系统综述和相应的荟萃分析。采用随机效应模型得出汇总相对风险。剂量-反应关系使用对数线性函数或立方样条得出:在已确定的 126 项符合条件的研究中,97 篇原创文章被纳入荟萃分析。总体暴露于 SHS 的肺癌汇总相对风险为 1.24(95% CI 1.16-1.32,文章数量,n=82)。在家中接触 SHS 的特定环境相对风险为 1.20(95% CI 1.12-1.28,n=67),在工作场所接触 SHS 的相对风险为 1.38(95% CI 1.28-1.62,n=30),在家中或工作场所接触 SHS 的相对风险为 1.37(95% CI 1.22-1.53,n=28),在非特定环境接触 SHS 的相对风险为 1.27(95% CI 1.11-1.44,n=24)。患肺癌的风险随着接触 SHS 的时间、强度和包年而明显增加:这项荟萃分析表明,暴露于 SHS 会使从不吸烟者罹患肺癌的风险增加 20% 以上,为 SHS 暴露与肺癌风险之间的关联提供了确凿证据。
{"title":"Association between second-hand smoke exposure and lung cancer risk in never-smokers: a systematic review and meta-analysis.","authors":"Irene Possenti, Marco Romelli, Giulia Carreras, Annalisa Biffi, Vincenzo Bagnardi, Claudia Specchia, Silvano Gallus, Alessandra Lugo","doi":"10.1183/16000617.0077-2024","DOIUrl":"10.1183/16000617.0077-2024","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer ranks as the leading cause of cancer-related deaths worldwide. There is evidence that second-hand smoke (SHS) exposure is a risk factor for the development of lung cancer in never-smokers. This systematic review and meta-analysis aims to provide the most accurate quantification of the association between SHS exposure and lung cancer risk in never-smokers.</p><p><strong>Materials and methods: </strong>Through the use of an innovative method to identify original publications, we conducted a systematic review of the literature, with corresponding meta-analysis, of all epidemiological studies evaluating the association between SHS exposure and lung cancer risk among never-smokers, published up to May 2023. Pooled relative risks were obtained using random-effects models. Dose-response relationships were derived using log-linear functions or cubic splines.</p><p><strong>Results: </strong>Out of 126 identified eligible studies, 97 original articles were included in the meta-analysis. The pooled relative risk for lung cancer for overall exposure to SHS was 1.24 (95% CI 1.16-1.32, number of articles, n=82). Setting-specific relative risks were 1.20 (95% CI 1.12-1.28, n=67) for SHS exposure at home, 1.38 (95% CI 1.28-1.62, n=30) at a workplace, 1.37 (95% CI 1.22-1.53, n=28) at home or a workplace and 1.27 (95% CI 1.11-1.44, n=24) in nonspecified settings. The risk of lung cancer significantly increased with the duration, intensity and pack-years of SHS exposure.</p><p><strong>Conclusions: </strong>This meta-analysis shows that exposure to SHS increases by more than 20% the risk of lung cancer among never-smokers, providing definitive evidence of the association between SHS exposure and lung cancer risk.</p>","PeriodicalId":12166,"journal":{"name":"European Respiratory Review","volume":"33 174","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-13Print Date: 2024-10-01DOI: 10.1183/16000617.0129-2024
Muhammed Afthab, Shadi Hambo, Hyunji Kim, Ali Alhamad, Hani Harb
Air pollution is one of the leading causes of early deaths worldwide, with particulate matter (PM) as an emerging factor contributing to this trend. PM is classified based on its physical size, which ranges from PM10 (diameter ≤10 μm) to PM2.5 (≤2.5 μm) and PM0.5 (≤0.5 μm). Smaller-sized PM can move freely through the air and readily infiltrate deep into the lungs, intensifying existing health issues and exacerbating complications. Lung complications are the most common issues arising from PM exposure due to the primary site of deposition in the respiratory system. Conditions such as asthma, COPD, idiopathic pulmonary fibrosis, lung cancer and various lung infections are all susceptible to worsening due to PM exposure. PM can epigenetically modify specific target sites, further complicating its impact on these conditions. Understanding these epigenetic mechanisms holds promise for addressing these complications in cases of PM exposure. This involves studying the effect of PM on different gene expressions and regulation through epigenetic modifications, including DNA methylation, histone modifications and microRNAs. Targeting and manipulating these epigenetic modifications and their mechanisms could be promising strategies for future treatments of lung complications. This review mainly focuses on different epigenetic modifications due to PM2.5 exposure in the various lung complications mentioned above.
空气污染是导致全球早期死亡的主要原因之一,而颗粒物(PM)是造成这一趋势的新因素。可吸入颗粒物根据其物理尺寸进行分类,从 PM10(直径≤10 μm)到 PM2.5(≤2.5 μm)和 PM0.5(≤0.5 μm)不等。尺寸较小的可吸入颗粒物可在空气中自由移动,并很容易渗入肺部深处,从而加剧现有的健康问题并加剧并发症。由于可吸入颗粒物主要沉积在呼吸系统,因此肺部并发症是接触可吸入颗粒物后最常见的问题。哮喘、慢性阻塞性肺病、特发性肺纤维化、肺癌和各种肺部感染等疾病都很容易因接触可吸入颗粒物而恶化。可吸入颗粒物可从表观遗传学上改变特定的靶位点,使其对这些疾病的影响更加复杂。了解这些表观遗传学机制有望解决暴露于可吸入颗粒物情况下的这些并发症。这涉及研究可吸入颗粒物通过表观遗传修饰(包括 DNA 甲基化、组蛋白修饰和微RNA)对不同基因表达和调控的影响。针对和操纵这些表观遗传修饰及其机制可能是未来治疗肺部并发症的有前途的策略。本综述主要关注PM2.5暴露在上述各种肺部并发症中导致的不同表观遗传修饰。
{"title":"Particulate matter-induced epigenetic modifications and lung complications.","authors":"Muhammed Afthab, Shadi Hambo, Hyunji Kim, Ali Alhamad, Hani Harb","doi":"10.1183/16000617.0129-2024","DOIUrl":"10.1183/16000617.0129-2024","url":null,"abstract":"<p><p>Air pollution is one of the leading causes of early deaths worldwide, with particulate matter (PM) as an emerging factor contributing to this trend. PM is classified based on its physical size, which ranges from PM<sub>10</sub> (diameter ≤10 μm) to PM<sub>2.5</sub> (≤2.5 μm) and PM<sub>0.5</sub> (≤0.5 μm). Smaller-sized PM can move freely through the air and readily infiltrate deep into the lungs, intensifying existing health issues and exacerbating complications. Lung complications are the most common issues arising from PM exposure due to the primary site of deposition in the respiratory system. Conditions such as asthma, COPD, idiopathic pulmonary fibrosis, lung cancer and various lung infections are all susceptible to worsening due to PM exposure. PM can epigenetically modify specific target sites, further complicating its impact on these conditions. Understanding these epigenetic mechanisms holds promise for addressing these complications in cases of PM exposure. This involves studying the effect of PM on different gene expressions and regulation through epigenetic modifications, including DNA methylation, histone modifications and microRNAs. Targeting and manipulating these epigenetic modifications and their mechanisms could be promising strategies for future treatments of lung complications. This review mainly focuses on different epigenetic modifications due to PM<sub>2.5</sub> exposure in the various lung complications mentioned above.</p>","PeriodicalId":12166,"journal":{"name":"European Respiratory Review","volume":"33 174","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-13Print Date: 2024-10-01DOI: 10.1183/16000617.0120-2024
Carla Ribeiro, Paula Pamplona, Anita K Simonds
Advance care planning (ACP) is a complex and iterative communication process between patients, surrogates and clinicians that defines goals of care that may include, but is not limited to, documentation of advance directives. The aim of ACP is to promote patient-centred care tailored to the patient's clinical situation through informed preparation for the future and improved communication between patient, clinicians and surrogates, if the latter need to make decisions on patient's behalf.The aim of this article is to review research related to ACP in acute and chronic respiratory failure, regarding the process, communication, shared decision-making, implementation and outcomes.Research has produced controversial results on ACP interventions due to the heterogeneity of measures and outcomes, but positive outcomes have been described regarding the quality of patient-physician communication, preference for comfort care, decisional conflict and patient-caregiver congruence of preferences and improved documentation of ACP or advance directives.The main barriers to ACP in chronic respiratory failure are the uncertainty of prognosis (particularly in the organ failure trajectory), the choice of the best timing for initiation and the lack of training of healthcare workers. In acute respiratory failure, the ACP process can be very short, should include the patient whenever possible, and is based on a discussion of treatments appropriate to the patient's functional status prior to the event (e.g. assessment of frailty) and clear communication of the likely consequences of possible options.All healthcare worker dealing with patients with serious illnesses should have training in communication skills to promote engagement in ACP discussions.
{"title":"Advance care planning in patients with respiratory failure.","authors":"Carla Ribeiro, Paula Pamplona, Anita K Simonds","doi":"10.1183/16000617.0120-2024","DOIUrl":"10.1183/16000617.0120-2024","url":null,"abstract":"<p><p>Advance care planning (ACP) is a complex and iterative communication process between patients, surrogates and clinicians that defines goals of care that may include, but is not limited to, documentation of advance directives. The aim of ACP is to promote patient-centred care tailored to the patient's clinical situation through informed preparation for the future and improved communication between patient, clinicians and surrogates, if the latter need to make decisions on patient's behalf.The aim of this article is to review research related to ACP in acute and chronic respiratory failure, regarding the process, communication, shared decision-making, implementation and outcomes.Research has produced controversial results on ACP interventions due to the heterogeneity of measures and outcomes, but positive outcomes have been described regarding the quality of patient-physician communication, preference for comfort care, decisional conflict and patient-caregiver congruence of preferences and improved documentation of ACP or advance directives.The main barriers to ACP in chronic respiratory failure are the uncertainty of prognosis (particularly in the organ failure trajectory), the choice of the best timing for initiation and the lack of training of healthcare workers. In acute respiratory failure, the ACP process can be very short, should include the patient whenever possible, and is based on a discussion of treatments appropriate to the patient's functional status prior to the event (<i>e.g.</i> assessment of frailty) and clear communication of the likely consequences of possible options.All healthcare worker dealing with patients with serious illnesses should have training in communication skills to promote engagement in ACP discussions.</p>","PeriodicalId":12166,"journal":{"name":"European Respiratory Review","volume":"33 174","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-30Print Date: 2024-10-01DOI: 10.1183/16000617.0166-2024
Thomas Bitter, Michael Arzt, Henrik Fox, Olaf Oldenburg, Christoph Schöbel
{"title":"Treating central sleep apnoea in heart failure: is positive airway pressure and adaptive servo-ventilation in particular the gold standard?","authors":"Thomas Bitter, Michael Arzt, Henrik Fox, Olaf Oldenburg, Christoph Schöbel","doi":"10.1183/16000617.0166-2024","DOIUrl":"10.1183/16000617.0166-2024","url":null,"abstract":"","PeriodicalId":12166,"journal":{"name":"European Respiratory Review","volume":"33 174","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11522996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-30Print Date: 2024-10-01DOI: 10.1183/16000617.0087-2024
Arietta Spinou, Annemarie L Lee, Brenda O'Neil, Ana Oliveira, Michal Shteinberg, Beatriz Herrero-Cortina
Bronchiectasis is a chronic lung condition which is characterised by recurrent chest infections, chronic sputum production and cough, and limited exercise tolerance. While bronchiectasis may be caused by various aetiologies, these features are shared by most patients with bronchiectasis regardless of the cause. This review consolidates the existing evidence on patient-managed interventions for adults with bronchiectasis, while also outlining areas for future research. Airway clearance techniques and hyperosmolar agents are key components of the bronchiectasis management and consistently recommended for clinical implementation. Questions around their prescription, such as optimal sequence of delivery, are still to be answered. Pulmonary rehabilitation and exercise are also recommended for patients with bronchiectasis. Relatively strong evidence underpins this recommendation during a clinically stable stage of the disease, although the role of pulmonary rehabilitation following an exacerbation is still unclear. Additionally, self-management programmes feature prominently in bronchiectasis treatment, yet the lack of consensus regarding their definition and outcomes presents hurdles to establishing a cohesive evidence base. Moreover, cough, a cardinal symptom of bronchiectasis, warrants closer examination. Although managing cough in bronchiectasis may initially appear risky, further research is necessary to ascertain whether strategies employed in other respiratory conditions can be safely and effectively adapted to bronchiectasis, particularly through identifying patient responder populations and criteria where cough may not enhance airway clearance efficacy and its control is needed. Overall, there is a growing recognition of the importance of patient-managed interventions in the bronchiectasis management. Efforts to improve research methodologies and increase research funding are needed to further advance our understanding of these interventions, and their role in optimising patient care and outcomes.
{"title":"Patient-managed interventions for adults with bronchiectasis: evidence, challenges and prospects.","authors":"Arietta Spinou, Annemarie L Lee, Brenda O'Neil, Ana Oliveira, Michal Shteinberg, Beatriz Herrero-Cortina","doi":"10.1183/16000617.0087-2024","DOIUrl":"10.1183/16000617.0087-2024","url":null,"abstract":"<p><p>Bronchiectasis is a chronic lung condition which is characterised by recurrent chest infections, chronic sputum production and cough, and limited exercise tolerance. While bronchiectasis may be caused by various aetiologies, these features are shared by most patients with bronchiectasis regardless of the cause. This review consolidates the existing evidence on patient-managed interventions for adults with bronchiectasis, while also outlining areas for future research. Airway clearance techniques and hyperosmolar agents are key components of the bronchiectasis management and consistently recommended for clinical implementation. Questions around their prescription, such as optimal sequence of delivery, are still to be answered. Pulmonary rehabilitation and exercise are also recommended for patients with bronchiectasis. Relatively strong evidence underpins this recommendation during a clinically stable stage of the disease, although the role of pulmonary rehabilitation following an exacerbation is still unclear. Additionally, self-management programmes feature prominently in bronchiectasis treatment, yet the lack of consensus regarding their definition and outcomes presents hurdles to establishing a cohesive evidence base. Moreover, cough, a cardinal symptom of bronchiectasis, warrants closer examination. Although managing cough in bronchiectasis may initially appear risky, further research is necessary to ascertain whether strategies employed in other respiratory conditions can be safely and effectively adapted to bronchiectasis, particularly through identifying patient responder populations and criteria where cough may not enhance airway clearance efficacy and its control is needed. Overall, there is a growing recognition of the importance of patient-managed interventions in the bronchiectasis management. Efforts to improve research methodologies and increase research funding are needed to further advance our understanding of these interventions, and their role in optimising patient care and outcomes.</p>","PeriodicalId":12166,"journal":{"name":"European Respiratory Review","volume":"33 174","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11522970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-30Print Date: 2024-10-01DOI: 10.1183/16000617.0012-2024
Angela T Burge, Adelle M Gadowski, Alice Jones, Lorena Romero, Natasha E Smallwood, Magnus Ekström, Lynn F Reinke, Ravijyot Saggu, Marlies Wijsenbeek, Anne E Holland
Background: In adults with serious respiratory illness, breathlessness is prevalent and associated with reduced health-related quality of life. The aim of this review was to assess the impact of breathing techniques on breathlessness in adults with serious respiratory illness.
Methods: Electronic databases were searched to identify randomised controlled trials testing breathing techniques (techniques that aim to alter the respiratory pattern, excluding respiratory muscle training) in people with serious respiratory illness. The primary outcome was breathlessness and secondary outcomes were health-related quality of life and adverse events. Two authors independently screened for inclusion, evaluated risk of bias and extracted data.
Results: 73 randomised controlled trials were included with 5479 participants, most with COPD or asthma. Breathing exercises (pursed lip and/or diaphragmatic breathing) reduced breathlessness measured by the modified Medical Research Council scale compared to usual care (mean difference (MD) -0.40 points, 95% CI -0.70- -0.11, eight studies, n=323), although the effect did not exceed the minimal important difference. Yoga breathing also improved modified Medical Research Council score compared to usual care (MD -1.05 points, 95% CI -2.45-0.35, three studies, n=175). Breathing techniques consistently improved health-related quality of life in people with COPD and asthma on multiple health-related quality of life measures in comparison to usual care, with effects that generally exceeded the minimal important difference. No adverse events related to breathing techniques were reported.
Conclusion: Breathing techniques may improve breathlessness, and consistently improve health-related quality of life, in people with serious respiratory illness. These findings support the use of breathing exercises in the care of people with serious respiratory illness.
背景:在患有严重呼吸系统疾病的成人中,呼吸困难是一种普遍现象,并与健康相关的生活质量下降有关。本综述旨在评估呼吸技巧对患有严重呼吸系统疾病的成年人呼吸困难的影响:对电子数据库进行了检索,以确定针对严重呼吸系统疾病患者测试呼吸技术(旨在改变呼吸模式的技术,不包括呼吸肌训练)的随机对照试验。主要结果是呼吸困难,次要结果是与健康相关的生活质量和不良事件。两位作者独立筛选纳入试验、评估偏倚风险并提取数据:结果:共纳入了 73 项随机对照试验,共有 5479 名参与者,其中大部分患有慢性阻塞性肺病或哮喘。与常规护理相比,呼吸练习(抿唇呼吸和/或横膈膜呼吸)减少了改良医学研究委员会量表测量的窒息感(平均差(MD)-0.40 分,95% CI -0.70--0.11,8 项研究,n=323),尽管效果未超过最小重要差异。与常规护理相比,瑜伽呼吸也能提高医学研究委员会的修正评分(MD -1.05分,95% CI -2.45-0.35,三项研究,人数=175)。与常规护理相比,呼吸技巧能持续改善慢性阻塞性肺病和哮喘患者在多种健康相关生活质量测量指标上的健康相关生活质量,其效果通常超过最小重要差异。没有与呼吸技巧相关的不良事件报告:呼吸技巧可改善呼吸困难,并持续改善严重呼吸系统疾病患者的健康相关生活质量。这些研究结果支持在重症呼吸系统疾病患者的护理中使用呼吸练习。
{"title":"Breathing techniques to reduce symptoms in people with serious respiratory illness: a systematic review.","authors":"Angela T Burge, Adelle M Gadowski, Alice Jones, Lorena Romero, Natasha E Smallwood, Magnus Ekström, Lynn F Reinke, Ravijyot Saggu, Marlies Wijsenbeek, Anne E Holland","doi":"10.1183/16000617.0012-2024","DOIUrl":"10.1183/16000617.0012-2024","url":null,"abstract":"<p><strong>Background: </strong>In adults with serious respiratory illness, breathlessness is prevalent and associated with reduced health-related quality of life. The aim of this review was to assess the impact of breathing techniques on breathlessness in adults with serious respiratory illness.</p><p><strong>Methods: </strong>Electronic databases were searched to identify randomised controlled trials testing breathing techniques (techniques that aim to alter the respiratory pattern, excluding respiratory muscle training) in people with serious respiratory illness. The primary outcome was breathlessness and secondary outcomes were health-related quality of life and adverse events. Two authors independently screened for inclusion, evaluated risk of bias and extracted data.</p><p><strong>Results: </strong>73 randomised controlled trials were included with 5479 participants, most with COPD or asthma. Breathing exercises (pursed lip and/or diaphragmatic breathing) reduced breathlessness measured by the modified Medical Research Council scale compared to usual care (mean difference (MD) -0.40 points, 95% CI -0.70- -0.11, eight studies, n=323), although the effect did not exceed the minimal important difference. Yoga breathing also improved modified Medical Research Council score compared to usual care (MD -1.05 points, 95% CI -2.45-0.35, three studies, n=175). Breathing techniques consistently improved health-related quality of life in people with COPD and asthma on multiple health-related quality of life measures in comparison to usual care, with effects that generally exceeded the minimal important difference. No adverse events related to breathing techniques were reported.</p><p><strong>Conclusion: </strong>Breathing techniques may improve breathlessness, and consistently improve health-related quality of life, in people with serious respiratory illness. These findings support the use of breathing exercises in the care of people with serious respiratory illness.</p>","PeriodicalId":12166,"journal":{"name":"European Respiratory Review","volume":"33 174","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11522968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-30Print Date: 2024-10-01DOI: 10.1183/16000617.0132-2024
Camille David, Charles Verney, Mustapha Si-Tahar, Antoine Guillon
Influenza A virus (IAV) is one of the leading causes of respiratory infections. The lack of efficient anti-influenza therapeutics requires a better understanding of how IAV interacts with host cells. Alveolar macrophages are tissue-specific macrophages that play a critical role in lung innate immunity and homeostasis, yet their role during influenza infection remains unclear. First, our review highlights an active IAV replication within alveolar macrophages, despite an abortive viral cycle. Such infection leads to persistent alveolar macrophage inflammation and diminished phagocytic function, alongside direct mitochondrial damage and indirect metabolic shifts in the alveolar micro-environment. We also discuss the "macrophage disappearance reaction", which is a drastic reduction of the alveolar macrophage population observed after influenza infection in mice but debated in humans, with unclear underlying mechanisms. Furthermore, we explore the dual nature of alveolar macrophage responses to IAV infection, questioning whether they are deleterious or protective for the host. While IAV may exploit immuno-evasion strategies and induce alveolar macrophage alteration or depletion, this could potentially reduce excessive inflammation and allow for the replacement of more effective cells. Despite these insights, the pathophysiological role of alveolar macrophages during IAV infection in humans remains understudied, urging further exploration to unravel their precise contributions to disease progression and resolution.
{"title":"The deadly dance of alveolar macrophages and influenza virus.","authors":"Camille David, Charles Verney, Mustapha Si-Tahar, Antoine Guillon","doi":"10.1183/16000617.0132-2024","DOIUrl":"10.1183/16000617.0132-2024","url":null,"abstract":"<p><p>Influenza A virus (IAV) is one of the leading causes of respiratory infections. The lack of efficient anti-influenza therapeutics requires a better understanding of how IAV interacts with host cells. Alveolar macrophages are tissue-specific macrophages that play a critical role in lung innate immunity and homeostasis, yet their role during influenza infection remains unclear. First, our review highlights an active IAV replication within alveolar macrophages, despite an abortive viral cycle. Such infection leads to persistent alveolar macrophage inflammation and diminished phagocytic function, alongside direct mitochondrial damage and indirect metabolic shifts in the alveolar micro-environment. We also discuss the \"macrophage disappearance reaction\", which is a drastic reduction of the alveolar macrophage population observed after influenza infection in mice but debated in humans, with unclear underlying mechanisms. Furthermore, we explore the dual nature of alveolar macrophage responses to IAV infection, questioning whether they are deleterious or protective for the host. While IAV may exploit immuno-evasion strategies and induce alveolar macrophage alteration or depletion, this could potentially reduce excessive inflammation and allow for the replacement of more effective cells. Despite these insights, the pathophysiological role of alveolar macrophages during IAV infection in humans remains understudied, urging further exploration to unravel their precise contributions to disease progression and resolution.</p>","PeriodicalId":12166,"journal":{"name":"European Respiratory Review","volume":"33 174","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11522969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}